ad image

Cardiovascular

1 / 1
Breaking the Cycle of Chronic Disease with New Therapeutic Strategies
Chronic Diseases

Breaking the Cycle of Chronic Disease with New Therapeutic Strategies

David Alvaro, Ph.D.

Pharma's Almanac

PAO-25-30-11Mar 02, 2025
Battling Ischemia with Therapeutic Angiogenesis
Ischemia

Battling Ischemia with Therapeutic Angiogenesis

Zhittya Genesis Medicine

PAO-03-22-R250-11Mar 15, 2022
Accelerated Drug Development for Acute Cardiovascular and Pulmonary Care

Accelerated Drug Development for Acute Cardiovascular and Pulmonary Care

Craig Fraser

PA822Aug 25, 2021
BioVectra and PhaseBio Discuss Creating an Optimal Partnership
Partnership

BioVectra and PhaseBio Discuss Creating an Optimal Partnership

Oliver Technow; David Alvaro, Ph.D.; Jonathan Mow

BIOVECTRA

PTV-04-21-CL-001Apr 15, 2021
AstraZeneca
Clinical Results

AstraZeneca's Drug Significantly Reduces the Rate of the Composite of Stroke and Death in Patients

AstraZeneca

PR-M07-20-NI-027Jul 16, 2020
Sanofi to Exit Diabetes and Cardiovascular Research
Diabetes

Sanofi to Exit Diabetes and Cardiovascular Research

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M12-19-NI-005Dec 13, 2019
CD34+ Cell Therapy in Clinical Trials
Cell Therapy

CD34+ Cell Therapy in Clinical Trials

Douglas Losordo

Lisata Therapeutics

PAP-Q4-19-CL-012Dec 06, 2019
Novartis
M&A

Novartis to Acquire The Medicines Company for $9.7 Billion

Novartis

PR-M11-19-NI-031Nov 25, 2019
Amgen
Drug Pricing

Amgen To Make Repatha® (evolocumab) Available Exclusively At Its Lower List Price Option In 2020

Amgen

PR-M10-19-NI-037Oct 25, 2019
Huma
Collaboration Agreement

Sensyne Health Signs Collaboration Agreement with Bayer to Accelerate the Treatments for Cardiovascular Disease Using Clinical Artificial Intelligence

Huma

PR-M08-19-NI-012Aug 05, 2019
U.S. Food & Drug Administration
FDA Approval

FDA Approves New Device for Treating Moderate to Severe Chronic Heart Failure in Patients

U.S. Food & Drug Administration

PR-M03-19-NI-068Mar 25, 2019
Novartis Licenses First-in-Class Heart Disease Drug
Drug Development

Novartis Licenses First-in-Class Heart Disease Drug

Emilie Branch

Pharma's Almanac

PAO-M03-19-NI-008Mar 05, 2019
BIS Research
Market Prediction

Global Interventional Cardiology Market to Reach $24.96 Billion by 2027

BIS Research

PR-M10-18-NI-098Oct 29, 2018
My Heart, Your Heart
Cardiovascular

World Heart Day: Nearly One in Five Deaths From Cardiovascular Disease are Caused by Air Pollution, a Total of 3 Million Deaths Globally Every Year

My Heart, Your Heart

PR-M10-18-NI-013Oct 03, 2018
Fish-Oil Drug Shows Dramatic Results in Cardiovascular Study
Clinical Results

Fish-Oil Drug Shows Dramatic Results in Cardiovascular Study

Emilie Branch

Pharma's Almanac

PAO-M09-18-NI-025Sep 25, 2018
Medicure
FDA Approval

Medicure Announces FDA Approval of Acute Care Cardiovascular Drug Sodium Nitroprusside Injection

Medicure

PR-M09-18-NI-020Sep 10, 2018
Janssen Pharmaceutical Companies
Cardiovascular

Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases

Janssen Pharmaceutical Companies

PR-M04-18-NI-72Apr 20, 2018
Positive Results for Pfizer Drug Tafamidis
Results

Positive Results for Pfizer Drug Tafamidis

Emilie Branch

Pharma's Almanac

PAO-M04-18-NI-001Apr 04, 2018
Harvard Researchers Use Chip Technology to Investigate New Anti-inflammatory Drugs
Innovation

Harvard Researchers Use Chip Technology to Investigate New Anti-inflammatory Drugs

Emilie Branch

Pharma's Almanac

PAO-M01-18-NI-034Jan 19, 2018
Secant Group
Cardiovascular

Secant Group Develops the First Synthetic Regenerative Cardiovascular Graft

Secant Group

PR-M01-18-NI-052-4856Jan 16, 2018
1 / 1